BIOLINERX     Print Page  Close Window

SEC filings
F-1
BIOLINERX LTD. filed this Form F-1 on 10/02/2012
Entire Document
 
F - 41

 
 
BioLineRx Ltd.
 
NOTES TO THE FINANCIAL STATEMENTS
 
NOTE 10 – TAXES ON INCOME (cont.)

 
f.
Deductible temporary differences
 
The amount of cumulative deductible temporary differences, other than unused tax loss carryforwards (as mentioned in c. above), for which a deferred tax asset has not been recognized in the statement of financial position as of December 31, 2010 was NIS 13,086,000. There were no cumulative deductible temporary differences, other than unused tax loss carryforwards, as of December 31, 2011. The temporary differences have no expiration dates.

 
g.
Value-added tax (VAT)
 
BioLineRx is jointly registered for VAT purposes together with its Israeli subsidiaries.
 
NOTE 11 – EARNINGS (LOSS) PER SHARE

 
a.
The following table contains the data used in the computation of the basic earnings (loss) per share:

   
Year ended December 31,
 
   
2009
   
2010
   
2011
 
   
NIS in thousands
 
Income (loss) attributed to ordinary shares
    (61,518 )     7,440       (50,186 )
Number of shares used in basic calculation (in thousands)
    96,693       123,512       123,603  
Adjustment for incremental dilutive shares from the theoretical exercise of options and warrants
    -       1,035       -  
Number of shares used in diluted calculation (in thousands)
    -       124,547       -  
                         
   
NIS
 
Basic earnings (loss) per ordinary share
    (0.63 )     0.06       (0.41 )
Diluted earnings (loss) per ordinary share
    (0.63 )     0.06       (0.41 )